| Typicality: | 0.263 |
| Saliency: | 0.236 |
| to be safe | 8 | purpose |
| in a phase 2a clinical trial | 5 | location |
| recently | 4 | temporal |
| vaccine → be shown to be → immunogenic | 14 |
| vaccine → prove to be → immunogenic | 3 |
| negative | neutral | positive |
| 0.032 | 0.208 | 0.760 |
| Raw frequency | 17 |
| Normalized frequency | 0.236 |
| Modifier score | 0.500 |
| Perplexity | 37.714 |